专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08790645B2 Pharmaceutical composition comprising a bispecific antibody for EpCAM 有权
标题翻译：包含用于EpCAM的双特异性抗体的药物组合物
公开(公告)号：US08790645B2
公开(公告)日：2014-07-29
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
IPC分类号： A61K39/395 , C07K16/00 , C07K16/30 , C07K16/28
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

2. 发明申请

US20100183615A1 CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS 审中-公开
标题翻译：跨物种特异性双重绑定
公开(公告)号：US20100183615A1
公开(公告)日：2010-07-22
申请号：US12594729
申请日：2008-04-03
申请人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbuese , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbuese , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , A61P35/00 , A61P37/00 , C12N15/74 , C12N5/10
CPC分类号： C07K16/2809 , C07K16/2863 , C07K16/30 , C07K16/3053 , C07K16/32 , C07K16/40 , C07K16/4291 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/32 , C07K2319/43
摘要： The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
摘要翻译：本发明涉及包含能够结合人和非黑猩猩灵长类CD3（ε）链的表位的第一人结合结构域和能够结合人的EGFR，Her2 / neu或IgE的第二结合结构域的多肽和/或非黑猩猩灵长类动物以及生产所述多肽的方法。本发明还涉及编码多肽的核酸，包含其的载体和包含载体的宿主细胞。另一方面，本发明提供包含所述多肽的药物组合物和多肽的医学用途。

3. 发明授权

US08901278B2 Pharmaceutical antibody compositions with resistance to soluble CEA 有权
标题翻译：具有抗CEA抗性的药物抗体组合物
公开(公告)号：US08901278B2
公开(公告)日：2014-12-02
申请号：US13324823
申请日：2011-12-13
申请人： Doris Rau , Susanne Mangold , Peter Kufer , Tobias Raum
发明人： Doris Rau , Susanne Mangold , Peter Kufer , Tobias Raum
IPC分类号： C07K16/30 , A61K39/00
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：（SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

4. 发明授权

US07632925B2 Antibodies that bind human 17-A1/EpCAM tumor antigen 有权
标题翻译：结合人17-A1 / EpCAM肿瘤抗原的抗体
公开(公告)号：US07632925B2
公开(公告)日：2009-12-15
申请号：US11860242
申请日：2007-09-24
申请人： Peter Kufer , Tobias Raum
发明人： Peter Kufer , Tobias Raum
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , C12P21/04 , C07H21/04
CPC分类号： C07K16/30 , A61K38/00 , C07K16/00 , C07K2317/34
摘要： The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.
摘要翻译：本发明提供在人体中低或不是免疫原性的抗人抗体或其片段。特别地，抗体或片段针对人肿瘤抗原，优选针对人肿瘤抗原17-1A，也称为EpCAM，EGP或GA 733-2。还提供了包含上述抗体或其片段的药物组合物。

5. 发明申请

US20090252683A1 Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof 有权
标题翻译：组成包括交叉物种 - 特异性抗体及其用途
公开(公告)号：US20090252683A1
公开(公告)日：2009-10-08
申请号：US12083351
申请日：2006-10-10
申请人： Roman Kischel , Tobias Raum , Bernd Schlereth , Doris Rau , Ronny Cierpka , Peter Kufer
发明人： Roman Kischel , Tobias Raum , Bernd Schlereth , Doris Rau , Ronny Cierpka , Peter Kufer
IPC分类号： A61K39/395 , C07K16/18 , C12N15/13 , C12N15/85 , C12N5/16 , C12P21/02 , A61P35/00 , A61B10/00
CPC分类号： A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2809 , C07K16/30 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/34 , C07K2317/56 , C07K2317/622
摘要： The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.
摘要翻译：本发明涉及显示跨物种特异性的双特异性抗体用于评估其在非人物种和人中的体内安全性和/或其活性和/或药代动力学特征的用途。本发明还涉及用于评估展示跨物种特异性的所述双特异性抗体的体内安全性和/或活性和/或药代动力学特征的方法。本发明还涉及测量显示跨物种特异性的这种双特异性抗体的生物活性和/或功效的方法。此外，本发明涉及包含显示跨物种特异性的双特异性单链抗体的药物组合物和用于制备药物组合物的方法，所述药物组合物包含显示针对疾病治疗疾病的跨物种特异性的所述双特异性单链抗体。

6. 发明申请

US20090241202A1 DOMAIN-GRAFTED ANTIBODIES 审中-公开
标题翻译： DOMAIN-GRAFTED抗体
公开(公告)号：US20090241202A1
公开(公告)日：2009-09-24
申请号：US12095822
申请日：2006-12-14
申请人： Peter Kufer , Tobias Raum , Petra Lutterbüse , Bernd Schlereth , Klaus Brischwein , Robert Hofmeister
发明人： Peter Kufer , Tobias Raum , Petra Lutterbüse , Bernd Schlereth , Klaus Brischwein , Robert Hofmeister
IPC分类号： A61K49/00 , C07K16/00 , C12N15/63 , C12N5/00 , C12P21/00
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/462 , C07K2317/732
摘要： The present invention relates to antibodies. Specifically, the present invention relates to antibodies composed of novel combinations of inter-species antibody domains (“domain-grafted antibodies”). The present invention further relates to compositions comprising such domain-grafted antibodies, as well as methods for producing such domain-grafted antibodies. Finally, the present invention relates to methods of evaluating the in vivo biological effect of such domain-grafted antibodies as well as uses of such domain-grafted antibodies for cross-species evaluation of the in vivo activity antibodies intended for human therapy.
摘要翻译：本发明涉及抗体。具体地，本发明涉及由物种间抗体结构域（“结构域接枝抗体”）的新型组合构成的抗体。本发明还涉及包含这种结构域接枝抗体的组合物，以及生产这种结构域接枝抗体的方法。最后，本发明涉及评价这种结构域接枝抗体的体内生物学效应的方法以及这种结构域接枝抗体用于物种评价用于人类治疗的体内活性抗体的用途。

7. 发明授权

US10981998B2 Cross-species-specific single domain bispecific single chain antibody 有权
公开(公告)号：US10981998B2
公开(公告)日：2021-04-20
申请号：US13122280
申请日：2009-10-01
申请人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffman , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffman , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： C07K16/28
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ϵ (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

8. 发明授权

US09587036B2 Cross-species-specific PSMAxCD3 bispecific single chain antibody 有权
标题翻译：跨物种特异性PSMAxCD3双特异性单链抗体
公开(公告)号：US09587036B2
公开(公告)日：2017-03-07
申请号：US13638223
申请日：2011-04-01
申请人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carola Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
发明人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carola Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
IPC分类号： C07K16/46 , A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/468 , C07K16/2809 , C07K16/30 , C07K16/3069 , C07K2317/31 , C07K2317/33 , C07K2317/622
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译：本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分身份证号 2,4,6和8以及能够结合前列腺特异性膜抗原（PSMA）的第二结合结构域。本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

9. 发明申请

US20120244162A1 CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS 审中-公开
标题翻译：跨物种特异性双重绑定
公开(公告)号：US20120244162A1
公开(公告)日：2012-09-27
申请号：US13408363
申请日：2012-02-29
申请人： Peter KUFER , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter KUFER , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： C07K16/46 , A61K39/395 , A61P35/00 , C12N1/19 , C12N15/63 , C12P21/00 , C12N1/21 , C12N5/10 , C12N15/13 , A61P37/00
CPC分类号： C07K16/2809 , C07K16/2863 , C07K16/30 , C07K16/3053 , C07K16/32 , C07K16/40 , C07K16/4291 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/32 , C07K2319/43
摘要： The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3ε (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide.
摘要翻译：本发明涉及包含可与人和非黑猩猩CD3抗原表位结合的第一人结合结构域的多肽; （ε）链和能够结合人和/或非黑猩猩灵长类动物的EGFR，Her2 / neu或IgE的第二结合结构域以及生产所述多肽的方法。本发明还涉及编码该多肽的核酸序列，包含核酸序列的载体和包含核酸序列或含有该核酸序列的载体的宿主细胞。另一方面，本发明提供了包含该多肽的药物组合物和该多肽的医学治疗或使用方法。

10. 发明申请

US20120121600A1 PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 有权
标题翻译：具有抗溶性CEA的药物抗体组合物
公开(公告)号：US20120121600A1
公开(公告)日：2012-05-17
申请号：US13324823
申请日：2011-12-13
申请人： Doris RAU , Susanne Mangold , Peter Kufer , Tobias Raum
发明人： Doris RAU , Susanne Mangold , Peter Kufer , Tobias Raum
IPC分类号： A61K39/395 , A61P35/00 , C07K16/32
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” or (ii) a CDR-H1 having the amino acid sequence “TYAMH” and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY”. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有氨基酸序列“SYWMH”和具有氨基酸序列“FIRNKANGGTTEYAASVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3或（ii）具有氨基酸序列“TYAMH”的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3。此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式